ALEX E. BROWN, M.D., F.A.C.P.; WALLACE E. HERRELL, M.D.; J. ARNOLD BARGEN, M.D., F.A.C.P.
This content is PDF only. Please click on the PDF icon to access.
With the advent of the various sulfamido compounds into the field of medical therapeutics it seemed reasonable, as we have stated in a previous article to investigate the effect of these preparations on patients who have chronic ulcerative colitis.
In using the term "chronic ulcerative colitis," we are referring only to the thrombo-ulcerative form of the disease in which destructive and hyperplastic changes occur in the bowel. We felt that such a trial of therapy was justified because it seemed likely that the organism responsible for the disease might be susceptible to the effect of these sulfamido compounds. In a
BROWN AE, HERRELL WE, BARGEN JA. NEOPRONTOSIL (ORAL) IN THE TREATMENT OF CHRONIC ULCERATIVE COLITIS*. Ann Intern Med. 1939;13:700–714. doi: https://doi.org/10.7326/0003-4819-13-4-700
Download citation file:
Published: Ann Intern Med. 1939;13(4):700-714.
Gastroenterology/Hepatology, Inflammatory Bowel Disease.
Results provided by:
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use